Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/54372
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMontemuiño Muñiz, Sara-
dc.contributor.authorMarcos Sánchez, Soraya-
dc.contributor.authorCalzas Rodríguez, Julia-
dc.contributor.authorLosada Vila, Beatriz-
dc.contributor.authorLlorente Herrero, Esther-
dc.contributor.authorHisado Díaz, María Dolores-
dc.contributor.authorValeri-Busto González, Victoria-
dc.contributor.authorTaboada Valladares, Begoña-
dc.contributor.authorVaquero Barrón, Blanca-
dc.contributor.authorMarcos Jimenez, Francisco José-
dc.contributor.authorAmor Alonso, Sergio-
dc.contributor.authorMoradiellos, Javier-
dc.contributor.authorRodríguez de Dios, Núria-
dc.contributor.authorCouñago, Felipe-
dc.date.accessioned2021-06-10T11:49:40Z-
dc.date.available2021-06-10T11:49:40Z-
dc.date.issued2021-04-22-
dc.identifier.citationJ Clin Transl Res.2021 Apr;(7)2:185-198es_ES
dc.identifier.urihttps://hdl.handle.net/20.500.12530/54372-
dc.description.abstractIn Stage IIIA-N2 non-small cell lung cancer (NSCLC), the accuracy of combined positron-emission tomography/computed tomography imaging (PET-CT), together with mediastinal staging techniques, has led to a wide range of challenging clinical scenarios in terms of therapeutic management. Concurrent chemoradiotherapy followed by consolidation immunotherapy remains the standard of care. In patients with potentially-resectable disease, surgery plays an important role in multimodal therapy. The introduction of targeted therapies and immune-checkpoint inhibitors has revolutionized multimodal treatment. In the present article, we review current treatment options and future trends in stage IIIA-N2 NSCLC.es_ES
dc.language.isoenes_ES
dc.relation.isversionofPreprintes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectchemoradiationes_ES
dc.subjectimmunotherapyes_ES
dc.subjectneoadjuvant treatmentes_ES
dc.subjectnon-small cell lung canceres_ES
dc.subjectstage IIIAes_ES
dc.subjectsurgeryes_ES
dc.subject.meshCarcinoma, Non-Small-Cell Lung-
dc.subject.meshCombined Modality Therapy-
dc.titleAdvances in multimodal treatment for stage IIIA-N2 non-small cell lung canceres_ES
dc.typeArtículoes_ES
dc.identifier.pubmedID34104821es_ES
dc.format.volume7es_ES
dc.format.page185-198es_ES
dc.description.peerreviewedes_ES
dc.identifier.journalJournal of clinical and translational researches_ES
dc.identifier.journalabbreviationJ Clin Transl Reses_ES
dc.contributor.authoraffiliationServicio de Oncología. Hospital Universitario de Fuenlabradaes_ES
dc.contributor.authoraffiliationServicio de Oncología Radioterápica Hospital Universitario de Fuenlabradaes_ES
dc.contributor.authoraffiliationServicio de Neumología. Hospital Universitario de Fuenlabradaes_ES
dc.contributor.authoraffiliationServicio de Medicina Nuclear. Hospital Universitario de Fuenlabradaes_ES
dc.format.number2es_ES
dc.subject.decsTerapia Combinada-
dc.subject.decsCarcinoma de Pulmón de Células no Pequeñas-
Appears in Collections:Hospitales > H. U. de Fuenlabrada > Artículos

Files in This Item:
File Description SizeFormat 
JCTRES.pdf583,7 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons